Compare NAII & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAII | PMI |
|---|---|---|
| Founded | 1980 | 1981 |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 14.1M |
| IPO Year | 1995 | N/A |
| Metric | NAII | PMI |
|---|---|---|
| Price | $2.48 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.1K | ★ 30.3M |
| Earning Date | 05-13-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $132,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.60 | N/A |
| 52 Week Low | $2.33 | $0.11 |
| 52 Week High | $4.96 | $13.68 |
| Indicator | NAII | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 38.13 |
| Support Level | $2.41 | $0.13 |
| Resistance Level | $2.86 | $0.27 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.74 | 9.23 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.